EVM
NVIV

Eaton Vance Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Eaton Vance Management’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Hold
0
– – – 2909
2021
Q4 		– Hold
0
– – – 2933
2021
Q3 		– Sell
-1
Closed -$16 – 2899
2021
Q2 		$0 Sell
1
-1
-50% -$19 ﹤0.01% 3150
2021
Q1 		$0 Buy
+2
New +$60 ﹤0.01% 2938

Other funds holding NVIV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

Eaton Vance Management's NVIV Position: Q1 2022 in Review

Eaton Vance Management held its InVivo Therapeutics Holdings Corp (NVIV) position steady in Q1 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2909.

Eaton Vance Management first reported a position in NVIV in Q1 2021 and has held it in 2 quarters since. The position peaked at $0 in Q2 2021. 16 funds tracked by Wall St. Rank hold NVIV as of Q1 2022.

  • Eaton Vance Management held 0 shares of InVivo Therapeutics Holdings Corp worth $0 as of Q1 2022.
  • Eaton Vance Management left its InVivo Therapeutics Holdings Corp share count unchanged in Q1 2022.
  • InVivo Therapeutics Holdings Corp made up ﹤0.01% of Eaton Vance Management's portfolio in Q1 2022, its #2909 holding.
  • Eaton Vance Management first reported a position in InVivo Therapeutics Holdings Corp in Q1 2021 and has held it in 2 quarters since.
  • Eaton Vance Management's InVivo Therapeutics Holdings Corp position peaked at $0 in Q2 2021.
  • 16 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.